Clinical trial
Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
NCT04439721 is registered in ClinicalTrials.gov with PersonGen BioTherapeutics (Suzhou) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
- Lead sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- May 1, 2020
- Completion date
- May 1, 2021
- Enrollment
- 5 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.